Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Efficacy And Safety ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(17)31191-1 ◽

2017 ◽

Vol 389 (10086) ◽

pp. 2287-2303 ◽

Cited By ~ 364

Author(s):

Andrew Blauvelt ◽

Marjolein de Bruin-Weller ◽

Melinda Gooderham ◽

Jennifer C Cather ◽

Jamie Weisman ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Term Management

Faculty Opinions recommendation of Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727591680.793534051 ◽

2017 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Term Management

Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.102 ◽

2020 ◽

Vol 4 (6) ◽

pp. s102

Author(s):

Stephan Weidinger ◽

Jonathan Silverberg ◽

Darryl Toth ◽

Thomas Bieber ◽

Andrew Alexis ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Abstract not available.

Faculty Opinions recommendation of Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727591680.793555533 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Term Management

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

JAMA Dermatology ◽

10.1001/jamadermatol.2020.3260 ◽

2020 ◽

Vol 156 (12) ◽

pp. 1333 ◽

Cited By ~ 2

Author(s):

Kristian Reich ◽

Kenji Kabashima ◽

Ketty Peris ◽

Jonathan I. Silverberg ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.99 ◽

2020 ◽

Vol 4 (6) ◽

pp. s99

Author(s):

Jonathan Silverberg ◽

Andrew Pink ◽

Christina Olsen ◽

Stephan Weidinger

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Abstract not available.

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(20)30732-7 ◽

2020 ◽

Vol 396 (10246) ◽

pp. 255-266 ◽

Cited By ~ 7

Author(s):

Eric L Simpson ◽

Rodney Sinclair ◽

Seth Forman ◽

Andreas Wollenberg ◽

Roland Aschoff ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind

28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.697 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB171

Author(s):

Andrew Blauvelt ◽

Michael R. Ardern-Jones ◽

Thomas Bieber ◽

Chih-ho Hong ◽

Chia-Yu Chu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.408 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB97

Author(s):

Andrew Blauvelt ◽

Emma Guttman-Yassky ◽

Amy S. Paller ◽

Eric L. Simpson ◽

John Browning ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Extension